UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 293

Sortiert nach

POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) + LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PHASE IB/II INTERIM ANALYSIS

Hematological oncology, 2019-06, Vol.37 (S2), p.175-176

2019

Volltextzugriff (PDF)

P1114: ZANDELISIB ON INTERMITTENT DOSING AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB OR ZANUBRUTINIB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): RESULTS FROM A MULTI‐ARM PHASE 1B STUDY

HemaSphere, 2022-06, Vol.6 (Suppl), p.1004-1005

2022

Volltextzugriff (PDF)

P1190: OUTCOMES BY BCL2 AND MYC EXPRESSION AND REARRANGEMENTS IN UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA FROM THE POLARIX TRIAL

HemaSphere, 2022-06, Vol.6 (Suppl), p.1076-1077

2022

Volltextzugriff (PDF)

Étude de l’effet du nintédanib sur les variations des biomarqueurs du renouvellement de la MEC chez les patients présentant une FPI et un déclin limité de la CVF : plan de l’étude INMARK

Revue des maladies respiratoires, 2019-01, Vol.36, p.A137-A138

2019

Volltextzugriff (PDF)

Prevalence of Zika Virus (Zikv) in blood donors from a hemotherapy service of the southern region of Brazil

ISBT science series, 2019-05, Vol.14 (2), p.157-162

2019

Volltextzugriff (PDF)

Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory NHL: A phase IB/II study

American journal of hematology, 2022-01, Vol.97, p.E24-E27

2022

Volltextzugriff (PDF)

P045 Lenticlair™ 1: A phase 1/2 trial evaluating the safety, tolerability and efficacy of an inhaled F/HN-pseudotyped lentiviral vector for CF gene therapy in people with CF ineligible for CFTR modulators

Journal of cystic fibrosis, 2024-06, Vol.23, p.S80-S80

2024

Volltextzugriff (PDF)

PP14. SSc-ILD患者の循環バイオマーカーへのニンテダニブの影響 (アンコール演題)

日本呼吸器学会誌, 2023-03, Vol.12 (suppl), p.215-215

2023

Volltextzugriff (PDF)

Final Result of DIAL (NCI10089), Randomized Phase 2 trial of Varlilumab combined with Nivolumab in patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma

Hematological oncology, 2023-06, Vol.41 (S2), p.592-594

2023

Volltextzugriff (PDF)

PP16. PF-ILD患者の循環バイオマーカーへのニンテダニブの影響 (アンコール演題)

日本呼吸器学会誌, 2023-03, Vol.12 (suppl), p.216-216

2023

Volltextzugriff (PDF)

Overall survival in classic Hodgkin lymphoma pts who progress after autologous stem cell transplant in the era of novel agents

Hematological oncology, 2023-06, Vol.41 (S2), p.366-368

2023

Volltextzugriff (PDF)

POLATUZUMAB VEDOTIN + RITUXIMAB + LENALIDOMIDE IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

Papilläres Fibroelastom der Aortenklappe -Eine seltene Ursache für einen thrombembolischen Hirninfarkt

Clinical research in cardiology, 2001-11, Vol.90 (11), p.872-874

2001

Volltextzugriff (PDF)

PROMISING CLINICAL DATA FROM DOSE ESCALATION IN A PHASE IB/II ONGOING STUDY OF MOSUNETUZUMAB WITH POLATUZUMAB VEDOTIN FOR RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMA

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

EXTENDED FOLLOW‐UP OF A PHASE I TRIAL OF IPILIMUMAB, NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN RELAPSED HODGKIN LYMPHOMA: A TRIAL OF THE ECOG‐ACRIN RESEARCH GROUP (E4412)

Hematological oncology, 2019-06, Vol.37 (S2), p.123-124

2019

Volltextzugriff (PDF)

D101 INFLAMMATION IN THE TRANSPLANTED LUNG AND FIBROSIS: Both Mmp-7 And Neutrophil Elastase Degraded Elastin Fragments Are Elevated In Idiopathic Pulmonary Fibrosis

American journal of respiratory and critical care medicine, 2015-01, Vol.191, p.1

2015

Volltextzugriff (PDF)

MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP‐UP DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (NHL)

Hematological oncology, 2019-06, Vol.37 (S2), p.310-311

2019

Volltextzugriff (PDF)

Koronare Stentimplantation ohne Vordehnung

Clinical research in cardiology, 1998-09, Vol.87 (9), p.707-714

1998

Volltextzugriff (PDF)

S102 POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) AND LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): INTERIM ANALYSIS OF A PHASE IB/II TRIAL

HemaSphere, 2019-06, Vol.3 (S1), p.2-3

2019

Volltextzugriff (PDF)

Einsatz des neuromuskulären Monitorings in Deutschland

Der Anaesthesist, 2003-06, Vol.52 (6), p.522-526

2003

Volltextzugriff (PDF)

A phase II, single-arm, open-label study of pralatrexate in patients with aggressive relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL): Study PDX-015

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e18568-e18568

2010

Volltextzugriff (PDF)

Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C

Blood cancer journal (New York), 2016-03, Vol.6, p.e402

2016

Volltextzugriff (PDF)

Neuromuscular blockade in the induction period?--Pro

Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 1999-05, Vol.34 (5), p.316

Diefenbach, C

1999

Volltextzugriff (PDF)

T-cell monomorphic post-transplant lymphoproliferative disorders (T-cell m-PTLD): Clinical characteristics and prognostic assessment of a serious complication after transplant

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.8056-8056

2010

Volltextzugriff (PDF)

A phase I study of NY-ESO-1 overlapping peptides with or without incomplete Freund's adjuvant and poly-ICLCL vaccination of ovarian cancer patients in second or third clinical remission

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.TPS174-TPS174

2010

Volltextzugriff (PDF)

1 – 25 von 293

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(189)
Mit Volltextzugriff
(241)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) + LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PHASE IB/II INTERIM ANALYSIS

P1114: ZANDELISIB ON INTERMITTENT DOSING AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB OR ZANUBRUTINIB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): RESULTS FROM A MULTI‐ARM PHASE 1B STUDY

P1190: OUTCOMES BY BCL2 AND MYC EXPRESSION AND REARRANGEMENTS IN UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA FROM THE POLARIX TRIAL

Étude de l’effet du nintédanib sur les variations des biomarqueurs du renouvellement de la MEC chez les patients présentant une FPI et un déclin limité de la CVF : plan de l’étude INMARK

Prevalence of Zika Virus (Zikv) in blood donors from a hemotherapy service of the southern region of Brazil

Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory NHL: A phase IB/II study

P045 Lenticlair™ 1: A phase 1/2 trial evaluating the safety, tolerability and efficacy of an inhaled F/HN-pseudotyped lentiviral vector for CF gene therapy in people with CF ineligible for CFTR modulators

PP14. SSc-ILD患者の循環バイオマーカーへのニンテダニブの影響 (アンコール演題)

Final Result of DIAL (NCI10089), Randomized Phase 2 trial of Varlilumab combined with Nivolumab in patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma

PP16. PF-ILD患者の循環バイオマーカーへのニンテダニブの影響 (アンコール演題)

Overall survival in classic Hodgkin lymphoma pts who progress after autologous stem cell transplant in the era of novel agents

POLATUZUMAB VEDOTIN + RITUXIMAB + LENALIDOMIDE IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL

Papilläres Fibroelastom der Aortenklappe -Eine seltene Ursache für einen thrombembolischen Hirninfarkt

PROMISING CLINICAL DATA FROM DOSE ESCALATION IN A PHASE IB/II ONGOING STUDY OF MOSUNETUZUMAB WITH POLATUZUMAB VEDOTIN FOR RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMA

EXTENDED FOLLOW‐UP OF A PHASE I TRIAL OF IPILIMUMAB, NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN RELAPSED HODGKIN LYMPHOMA: A TRIAL OF THE ECOG‐ACRIN RESEARCH GROUP (E4412)

D101 INFLAMMATION IN THE TRANSPLANTED LUNG AND FIBROSIS: Both Mmp-7 And Neutrophil Elastase Degraded Elastin Fragments Are Elevated In Idiopathic Pulmonary Fibrosis

MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP‐UP DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (NHL)

Koronare Stentimplantation ohne Vordehnung

S102 POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) AND LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): INTERIM ANALYSIS OF A PHASE IB/II TRIAL

Einsatz des neuromuskulären Monitorings in Deutschland

A phase II, single-arm, open-label study of pralatrexate in patients with aggressive relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL): Study PDX-015

Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C

Neuromuscular blockade in the induction period?--Pro

T-cell monomorphic post-transplant lymphoproliferative disorders (T-cell m-PTLD): Clinical characteristics and prognostic assessment of a serious complication after transplant

A phase I study of NY-ESO-1 overlapping peptides with or without incomplete Freund's adjuvant and poly-ICLCL vaccination of ovarian cancer patients in second or third clinical remission

Aktive Filter

Suchergebnisse filtern